Clinical Trial

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-11-08; most recent amendment 2025-06-17.
Status change: Completed → Recruiting 2025-06-17
Status change: Recruiting → Completed 2025-03-21
Trial Details
NCT Number NCT05618041
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
Enrollment 50 participants
Start Date 2022-09-07
Primary Completion 2027-09-06 (estimated)
Study Completion 2027-12-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-24